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Data are presented from a comparative research on expression fepidermal growth factor (EGF) receptors and response 
to EGF of six independently established cell ines derived from human hepatoma. These lines differ in terms of the degree 
of differentiation, presence ofhepatitis B virus (HBV) DNA copies in integrated form and expression fHBV genes. 
Our results indicate differential expression fmembrane EGF receptors and differential response toEGF under serum- 
and hormone-free culture conditions. Furthermore, a significant difference inaffinity could be detected between EGF 
receptors of the two highly dedifferentiated c lllines (HA22T/VGH and Li7A) whose replication is inhibited by EGF 
concentrations capable of stimulating more differentiated phenotypes. 
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1. INTRODUCTION 
Human hepatocellular carcinoma (HCC)- 
derived cell lines are characterized by the 
maintenance of the degree of cellular differentia- 
tion in culture [1]; furthermore, some are able to 
grow under completely serum- and hormone-free 
culture conditions [2,3]. This independence from 
growth factor requirements raises the question of 
whether products of activated cellular oncogenes 
(c-oncs) are involved in the process of liver car- 
cinogenesis [4-7] and activation of c-oncs in HCC 
tissues has recently been demonstrated [8-12]. 
A further aspect of HCC cells in culture has been 
reported concerning their response to polypeptide 
mitogens [13-15], thus indicating that at least in 
some cases epidermal growth factor (EGF) can 
play a major role in conditioning the growth 
characteristics of these cells. 
EGF is also known to be necessary in the 
regenerative process of the liver [16]; furthermore, 
in recent years, several sources of evidence have im- 
plicated EGF in the process of neoplastic transfor- 
mation [17-19]. 
For these main reasons, we have used a wide 
range of HCC cell lines, independently established 
and showing a different degree of differentiation, 
in order to study the presence and the integration 
of HBV DNA sequences, the expression of EGF 
receptors (EGF-Rs) and the effect of EGF on cell 
replication. 
The principal aim of this research as been to 
observe whether overexpressed EGF-Rs are involv- 
ed in the aberrant growth characteristics of HCC- 
derived cell lines. 
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2. MATERIALS AND METHODS 
2.1. Human hepatoma-derived c ll lines and cell cultures 
The HCC-derived cell lines studied were cultured in RPMI 
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1640 supplemented with 10% fetal calf serum (FCS), glutamine 
(2 mM) and antibiotics. The PLC/PRF/5 cell line was a gift 
from Dr Alexander, HA22T/VGH was obtained from Dr 
Chang, the HCC36 cell ine was kindly donated by Dr Chart and 
the HepG2, Hep3B and Li7A cell lines were a gift from Dr 
Knowles. The A431 human epidermoid carcinoma cell line was 
supplied by the European Collection of Animal Cell Cultures 
(Salisbury, England). 
The degree of cellular differentiation of the different HCC 
cell lines, based on both production of plasma proteins and the 
levels of major class I histocompatibility antigens induced by in- 
terferon 7, has been described elsewhere [1,2,13,14,19-23]. 
Serum-free cultures were grown using RPMI 1640 sup- 
plemented with 10 -8 M Na2SeO3 [12,13] while, for dose- 
response xperiments, 5x 104 cells were plated onto serum- 
containing medium which was renewed 24 h later using fresh 
RPMI 1640 supplemented with selenium as described above. 
The cells were counted at day 5 using a ZM Coulter Counter 
(Coulter Electronics, UK). 
2.2. Materials 
EGF from mouse submaxillary glands was supplied by Sigma 
(St. Louis, MO) and the monoclonal ntibody to the A431 EGF- 
R was supplied by Oncogene Science (Mineola, NY). 
HBsAg produced by several HCC cell lines was assayed inthe 
cell cytoplasm using a rabbit anti-HBs antiserum supplied by 
Behringwerke (Marburg) and again in the crude supernatants 
using a commercial enzyme immunoassay (Connaught, 
Willowdale, Canada). 
~25I-EGF was purchased from Biodata (Milan). 
2.3. Detection of hepatitis B virus DNA sequences 
Southern blot analysis of integrated HBV DNA sequences 
was performed on cell DNAs extracted using a standard pro- 
cedure [24]. Hybridization was carried out as in [25] using a 
complete 3.2 kilobase pair (kb) HBV genome [26]. 
2.4. EGF receptors 
125I-EGF binding to HCC cells was assayed using a previously 
described procedure with minor modifications [14]. 
Briefly, cells growing in 4-well tissue culture dishes were 
counted, rinsed using phosphate-buffered saline (PBS) and 0.1 
M Hepes buffer containing 0.5 #g/ml 125I-EGF (spec. act. 
2.5-3.5 × lO s cpm/ng) was added. 
After incubation, cells were washed using PBS supplemented 
with 1 mg/ml bovine serum albumin (BSA) (pH 7.0) and lysed 
by treatment with lysis buffer (0.1 M NaOH, 2°70 Na2CO3 and 
1 °7o SDS). Radioactivity was determined using a -r-counter. 
All cell lines were incubated at 4, 24 and 37°C; 24°C proved 
to be the most suitable temperature (not shown). Initially, 
binding experiments were similarly performed under different 
pH conditions. Non-specific binding was determined in the 
presence of a 200-fold excess of unlabeled EGF. 
Binding experiments for Scatchard analysis of EGF-receptor 
affinity were performed using a binding buffer containing in- 
creasing concentrations of 1251-EGF (0.1-10/zg/ml). Plates were 
incubated at 24°C for 3 h in order to approach equilibrium con- 
ditions for all cell lines. Finally, cells were rinsed with PBS and 
prepared for yg-counting as above. 
~2~I:EGF degradation was assayed in the presence of 10070 
trichloroacetic a id. 
Finally, we assayed the effect of a monoclonal antibody 
(mAb) to the A431 EGF receptor on EGF binding. The treat- 
ment with mAb (6.25/zg/ml) for 30 minutes at 37°C was seen to 
be effective in reducing A431 EGF binding by up to 80°7o (not 
shown). We thus used this treatment to study the comparative 
EGF binding of HCC cells in the presence of this mAb. 
3. RESULTS 
3.1. 125I-EGF binding to membrane receptors of  
HCC cells 
Fig. l  shows 125I-EGF binding of the HCC cell 
lines studied. The HA22T/VGH and PLC/PRF /5  
cell lines reached a steady state of binding within 60 
min, whereas 80-120 min incubat ion with labeled 
EGF was required for other cell lines, Among the 
cell lines tested, Li7A cells reached the highest level 
of binding (bound/tota l  = 24.6), although a 
discrete level of non-specific binding was observed 
which increased with time, 
Scatchard analysis of EGF-R aff inity principally 
shows the great diversity between the high Ka value 
of the HA22T/VGH EGF-R (8.4 x 101°) and that 
of Li7A EGF-R (undetectably low values). 
HCC cell lines were also treated with an mAb to 
A431 (human epidermoid carcinoma cell line) 
EGF-R capable of reducing 125I-EGF binding in 
this cell line by up to 80070 when used at 6.25/zg/ml 
(not shown) (table 1). Under the same experimental 
condit ions, although a marked decrease in 125I- 
EGF  binding to HA22T/VGH cells could be 
detected, we only observed minimal  (3°70 mAb-  
dependent inhibit ion of Li7A binding activity. 
3.2. Effect o f  EGF on HCC cell replication 
The different cell lines under study exhibited a 
differential capabil ity of replicating under serum- 
free condit ions (fig.2) and a differential attach- 
ment to the solid surface after plating. Seeding effi- 
ciencies were evaluated and ranged from lower 
values for less differentiated phenotypes (HA22T/  
VGH 54°70; Li7A 72°70; HCC36 74°70 to higher effi- 
ciencies for more differentiated HCC-cell lines 
(PLC/PRF /5 ,  HepG2 and Hep3B). This is prob- 
ably due to the different expression and release of 
serum factors which are involved in the seeding 
events. 
However, although we observed large dif- 
ferences in terms of cell replication among the cell 
lines under study, in a 5-day experiment, all cells 
were able to grow under the described conditions 
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Fig. I. J2~I-EGF binding to HCC cell lines (B/T, bound/total; incubation period in min). The dashed line represents non-specific bin- 
ding. Scatchard plots of EGF-receptor affinities are enclosed for each cell line (B/F, bound/free). Numbers represent the Ka values 
calculated (× 101°); this could not be evaluated for Li7A cells, a, HA22T/VGH; b, Li7A; c, HCC36; d, Hep3B; e, PLC/PRF/5; f, 
HepG2. 
showing  at least one doubl ing ,  with reference to the 
actua l  init ial  input  o f  a t tached cells. 
On ly  two  HCC-der ived  cell l ines (HA22T/VGH 
and  L i7A)  were inhib i ted in terms o f  cell repl ica- 
t ion  by increas ing concentrat ions  o f  EGF  in dose-  
response xper iments  (f ig.2). A l l  o ther  cell l ines ex- 
cept  one showed a smal l  mi togen ic  response to 
EGF  with in  d i f ferent  ranges,  the except ion  being 
HepG2 (a well  d i f ferent iated HCC cell l ine), whose  
cell rep l icat ion proved  to be st imulated up to 
Table 1 
Comparative analysis of six HCC-derived cell lines in culture 
Cell line Degree of HBV DNA HBsAg EGF-receptor affinity 
differentiation (copy no.) expression Ka (× l01°) mAb 
HA22T/VGH low + (3) - 8.4 55 
Li7A low - - ND 3 
HCC36 medium + (4) - 1.1 54 
PLC/PRF/5 high + (7) + 1.6 47 
Hep3B very high + (2) + 1.13 54 
HepG2 very high - - 1.6 66 
See section 2. Affinity of EGF-receptors (expressed as Ka X 101°) was determined by Scatchard 
analysis (ND, undetectable under our experimental conditions). The Ka value of the A431 human 
epidermoid carcinoma cell line EGF-R resulted to he 3.6 x 10 ~°. mAb: inhibition, expressed as per 
cent vs controls, of 125I-EGF binding observed after incubation of cells (30 min at 37°C) with a 
monoclonal antibody to the A431 EGF-R 
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Fig.2. Dose-response curves for EGF of serum-free cultured 
HCC cell lines. 5 x 104 cells were plated in a medium containing 
1007o FCS; culture medium was discarded at day 1 and fully 
serum- and hormone-free, selenium-supplemented RPMI 1640 
containing different amounts of EGF (0.05-100 ng/ml) was 
added. Seeding efficiencies were calculated for each cell line 12 
h after plating: HA22T/VGH, 5407o; Li7A, 72070; HCC36, 7407o; 
Hep3B, 90070; PLC/PRF/5 and Li7A, above 95°7o. Ceils were 
counted at day 5. Each point represents he mean of four dif- 
ferent replicates. Two to three experiments were performed for 
each aspect and all standard errors were less than 1007o. a, 
HA22T/VGH; b, Li7A; c, HCC36; d, Hep3B; e, PLC/PRF/5, 
f, HepG2. 
3-times vs controls using EGF concentrations 
above 10 ng/ml.  
3.3. Southern blot analysis of HBV DNA and 
expression of the HB V S gene 
HindlII-digested cell DNAs (fig.3) showed the 
presence of integrated HBV DNA sequences in 
four out of  six HCC cell lines (lanes a,b,d,e). 
However, only two HBV DNA-posit ive cell lines 
(PLC/PRF /5  and Hep3B) were seen to produce 
HBsAg and release it into the culture medium 
(table 1). 
4. D ISCUSION 
We have reported the differential expression of  
EGF-Rs in six independently established HCC cell 
lines and found that an inhibitory response to EGF 
Kbp a b c d e f 
21 .2-  
7.4~ 
5.6--  
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Fig.3. Integrated HBV DNA sequences showed by Southern 
blot analysis of HindlIl-digested cell DNAs. a, HA22T/VGH; 
b, HCC36; c, Li7A; d, PLC/PRF/5; e, Hep3B; f, HepG2. 
in terms of  cell replication occurs only in two 
highly dedifferentiated cell lines (Li7A and 
HA22T/VGH)  exhibiting quite different EGF-R 
affinity. These data are at variance with those of  
others which suggest hat either EGF-R expression 
is decreased in hepatoma cells [27], or that abnor- 
mal expression of  the EGF-R of HCC-cells is not 
among the factors responsible for the aberrant cell 
proliferation [15]. 
EGF has been observed to inhibit growth in vitro 
of  a variety of  carcinoma-derived cell lines [28-31], 
most of  which exhibit high levels of  high-affinity 
EGF  receptors as a consequence of gene amplifica- 
tion. It has been proposed that this EGF-l inked in- 
hibition of  cell replication may be due to excessive 
kinase stimulation, which depletes cellular energy 
stores [32]. 
To our knowledge, no cell line expressing a high 
level of  low-affinity EGF-Rs has been observed to 
be inhibited by EGF in cell proliferation. The Li7A 
cell line has exhibited a particularly high level of  
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125I-EGF binding, dependent mainly on overex- 
pressed low-affinity EGF-Rs and only minimal ly 
on high-aff inity EGF-Rs, thus being a possible tool 
for testing EGF- l inked inhibit ion of cell replica- 
t ion. On the other hand, HA22T/VGH EGF-Rs 
are represented by a single class of receptors with a 
particularly high level of affinity. 
Since the EGF-R is the product of the c-erb-B 
proto-oncogene [33], which is amplif ied in many 
cells of cancer origin [34] and its l igand TGF (an 
EGF- fami ly  protein) is also expressed in many 
cancer cells [35], product ion of EGF receptors may 
be closely related to mechanisms of oncogenesis. 
The present data taken together show that HCC-  
cell lines may exhibit overexpression f EGF-Rs at 
least in some cases. This may be responsible for the 
modif ied characteristics of cell replication and it 
opens up the question of whether activation and/or  
ampli f icat ion of the c-erb-B proto-oncogene oc- 
curs, thus supporting the possible role of this 
mechanism in the onset and development of liver 
cancer [36]. 
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